Puncharas Weerasubpong

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Omalizumab has been approved for the treatment of recalcitrant chronic spontaneous urticaria (CSU). However, it remains unanswered whether omalizumab modifies a CSU course. We aimed to study a course of CSU after omalizumab treatment in an Asian population. Medical records of recalcitrant CSU patients who attended Siriraj Hospital between 2013 and 2017 were(More)
  • 1